Holographic Description of AdS Cosmologies

To gain insight in the quantum nature of the big bang, we study the dual field theory description of asymptotically anti-de Sitter solutions of supergravity that have cosmological singularities. The dual theories do not appear to have a stable ground state. One regularization of the theory causes the cosmological singularities in the bulk to turn into giant black holes with scalar hair. We interpret these hairy black holes in the dual field theory and use them to compute a finite temperature effective potential. In our study of the field theory evolution, we find no evidence for a "bounce" from a big crunch to a big bang. Instead, it appears that the big bang is a rare fluctuation from a generic equilibrium quantum gravity state.Comment: 34 pages, 8 figures, v2: minor changes, references adde

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049

Review of "Thomas Traherne and Seventeenth-Century Thought, edited by Elizabeth S. Dodd and Cassandra Gormans.

Elizabeth S. Dodd and Cassandra Gorman eds. Thomas Traherne and Seventeenth-Century Thought. Cambridge: D.S. Brewer, 2016. xx + 220 pp. $99.00. Review by Gary Kuchar, University of Victoria